MyCural Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Early Stage VC
- Investors
-
8
MyCural Therapeutics General Information
Description
Developer of novel cancer therapies intended to fight high-risk tumors. The company identifies drug candidates and develops methods to kill MYC-driven tumor cells and spare normal cells, enabling healthcare workers to treat patients fighting cancer.
Contact Information
Website
www.mycural.comCorporate Office
- Arena Magasin X
- Sidenvävargatan 17
- 756 51 Uppsala
- Sweden
Corporate Office
- Arena Magasin X
- Sidenvävargatan 17
- 756 51 Uppsala
- Sweden
MyCural Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 01-Aug-2024 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Sep-2022 | Completed | Generating Revenue | |||
| 1. Seed Round | 01-Jan-2022 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
MyCural Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MyCural Therapeutics Patents
MyCural Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202414343-D0 | New compounds and medical uses thereof | Pending | 30-Sep-2024 | ||
| GB-202414345-D0 | New compounds and medical uses thereof | Pending | 30-Sep-2024 | ||
| GB-202414337-D0 | New compounds and medical uses thereof | Pending | 30-Sep-2024 | ||
| GB-202205404-D0 | Novel compounds and medical uses thereof | Inactive | 22-Dec-2021 | ||
| EP-4452268-A1 | Novel pyridocarbazolium compounds and medical uses thereof | Pending | 22-Dec-2021 | A61K31/475 |
MyCural Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MyCural Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ArnDahl | Venture Capital | Minority | ||
| Arcandis | Corporation | Minority | ||
| Life Science Invest | Venture Capital | Minority | ||
| LiU Invest | Venture Capital | Minority | ||
| Optigas | Corporation | Minority |
MyCural Therapeutics FAQs
-
When was MyCural Therapeutics founded?
MyCural Therapeutics was founded in 2022.
-
Where is MyCural Therapeutics headquartered?
MyCural Therapeutics is headquartered in Uppsala, Sweden.
-
What is the size of MyCural Therapeutics?
MyCural Therapeutics has 7 total employees.
-
What industry is MyCural Therapeutics in?
MyCural Therapeutics’s primary industry is Biotechnology.
-
Is MyCural Therapeutics a private or public company?
MyCural Therapeutics is a Private company.
-
What is MyCural Therapeutics’s current revenue?
The current revenue for MyCural Therapeutics is .
-
Who are MyCural Therapeutics’s investors?
ArnDahl, Arcandis, Life Science Invest, LiU Invest, and Optigas are 5 of 8 investors who have invested in MyCural Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
